Kerala Daily

Ocular Inflammation and Pain Market Is Expected to Grow during the Forecast Period (2019-2032), DelveInsight

 Breaking News
  • No posts were found

Ocular Inflammation and Pain Market Is Expected to Grow during the Forecast Period (2019-2032), DelveInsight

June 07
01:55 2022
Ocular Inflammation and Pain Market Is Expected to Grow during the Forecast Period (2019-2032), DelveInsight

DelveInsight’s Ocular Inflammation and Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Ocular Inflammation and Pain Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).


The Ocular Inflammation and Pain Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.


Ocular Inflammation and Pain: An Overview

Ocular Inflammation and Pain is the inflammation of the eye causing pain, it often results from an infection by viruses or bacteria. But inflammation of the eye can also be nonspecific. Ocular inflammation can be caused by a number of different etiological mechanisms. These include allergens, contact lens wear, trauma and dietary or lifestyle changes. While there are different “triggers” of ocular inflammation, they produce similar symptoms because all induce essentially the same immunological cascades. The “irritation” produced is caused by the induction of the interleukin system, immune cell recruitment and complement activation.


Get access to a free copy of our latest sample report @


Some of the key highlights of the Ocular Inflammation and Pain Market Report

  • According to Elizabeth Esterberg et al., in an article “Incidence and Prevalence of Uveitis Results From the Pacific Ocular Inflammation Study”, Uveitis is a set of conditions defined by intraocular inflammation and is believed to be the cause of up to 10% of legal blindness in the United States, or approximately 30 000 new cases of blindness per year.
  • As per Tiihonen et al. 2013, although cataract extraction is common, little is known about postoperative recovery and pain after phacoemulsification with IOL implantation. Postoperative pain is relatively common during the first hours after surgery and studies show that around ~34% of the cases experience such symptoms.
  • Cataract is more common among females as compared to males.


Ocular Inflammation and Pain Market

The Ocular Inflammation and Pain market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Ocular Inflammation and Pain Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Ocular Inflammation and Pain Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Ocular Inflammation and Pain Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.


Download Free Sample Report @


Ocular Inflammation and Pain Epidemiology

The epidemiology section covers insights into the historical and current Ocular Inflammation and Pain Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Ocular Inflammation and Pain Market Drugs & Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Inflammation and Pain Market or expected to get launched in the market during the study period. The analysis covers Ocular Inflammation and Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Ocular Inflammation and Pain Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Ocular Inflammation and Pain include therapies that are oral, anthracycline sparing and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.


Browse More Related Reports @


Ocular Inflammation and Pain Treatment Market

The mainstay of non-infectious uveitis treatment is corticosteroids, which are administered in three forms: topically, locally via sub-Tenon’s or intravitreal injection, and systemically. Immunomodulating drugs may be added to the corticosteroid regimen to eliminate the need for high doses of systemic steroids, or used alone as steroid-sparing agents when steroids are not tolerated. Pharmacological agents used as part of immunomodulatory therapy (IMT) can also have potential adverse events, and thus must be used by physicians who have had extensive experience in administering them. Primarily, four steroids are available: prednisolone, fluorometholone, dexamethasone and medrysone. On the horizon are two new “soft” steroids that have good anti-inflammatory effect but are metabolized quickly, thus reducing side effects and the likelihood of raising intraocular pressure (IOP).


Ocular Inflammation and Pain Market Insights

Inflammation after cataract surgery, which can be persistent, remains an undesirable consequence despite many advances in surgical techniques. Although corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have traditionally been used to treat inflammation, prophylactically as well as post-operatively, there are no established guidelines for the treatment of inflammation induced by cataract surgery.


Ocular Inflammation and Pain Market Dynamics

The dynamics of Ocular Inflammation and Pain market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the complication, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2032.


Discover more information about the report @


Table of content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis
  4. Market Overview at a Glance
  5. Disease Background and Overview
  6. Patient Journey
  7. Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Ocular Inflammation and Pain Market Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States